SCHEMBL1482341

SCHEMBL1482341

Oc1cc(Cl)ccc1-c1nc2cc(F)c(F)cc2n1Cc1cccc(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.47
RCE1 Q9Y256 1/20 0.47
CASR P41180 3/20 0.44
TP53 P04637 2/20 0.43
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MEN1 O00255 2/20 0.41
PLA2G2A P14555 1/20 0.41
ALDH1A1 P00352 3/20 0.40
SOS1 Q07889 1/20 0.40
HTT P42858 1/20 0.40
CCR2 P41597 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
MAPK10 P53779 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2B Q13224 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1482410 0.93 KMT2A (0.52) KMT2ARCE1CASRMAPTSMN1; SMN2
SCHEMBL1482808 0.89 CCR2 (0.49) KMT2ARCE1CASRMEN1SOS1
SCHEMBL1482490 0.85 DRD2 (0.49) KMT2AMAPTCCR2MAPK10
SCHEMBL1482892 0.85 KMT2A (0.45) KMT2ARCE1TP53MAPTSMN1; SMN2
SCHEMBL1482659 0.85 KMT2A (0.47) KMT2ARCE1CASRTP53MAPT
SCHEMBL1482748 0.84 DRD2 (0.41) KMT2ASOS1CCR2NPSR1
SCHEMBL1482375 0.83 SOS1 (0.39) KMT2ACASRSOS1NPSR1
SCHEMBL1482932 0.82 KDM4E (0.60) KMT2ARCE1TP53MAPTSMN1; SMN2
SCHEMBL1483164 0.81 DHFR (0.44) KMT2ARCE1TP53MAPTSMN1; SMN2
SCHEMBL1483090 0.80 TBXA2R (0.46) KMT2AMAPTSMN1; SMN2SOS1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309581-B2 Benzimidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2012-11-13 US disclosed
EP-2483247-A1 NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS F. Hoffmann-La Roche AG (CH) 2012-08-08 EP disclosed
WO-2011039130-A1 NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2011-04-07 WO disclosed
US-20110077273-A1 NEW BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077273-A1 NEW BENZIMIDAZOLE DERIVATIVES BRI3BP, CYP3A4, RB1 KMT2A 2176/4885RCE1 1657/4885CASR 3683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.